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ABBREVIATIONS & STATISTICAL FORMULAE 
ANC   – Absolute Neutrophil count 
AGEs   – Advanced Glycosylation End products 
CGD   – Chronic Granulomatous Disease 
C.I   – Confidence Interval (Mean +/- 2SE) i.e., 
95% of the  
means from similar samples drawn from 
the same population will have their value 
within the limits of two SE. 
DLC   – Differential Leucocyte Count 
EDTA   - Ethylene Diamine Tetraacetic Acid 
ESR   – Erythrocyte Sedimentation Rate 
FBS   – Fasting Blood Sugar 
FMLP   –  Formyl  Methionyl – leucyl  - phenylalanine  
n   – number of cases 
n1   - number of cases (1st category) 
n2   - number of cases (2nd category) 
NADPH  – Nicotinamide adenine dinucleotide 
phosphate  
(reduced) 
NAP   – Neutrophil Alkaline Phosphatase 
NBT   – Nitroblue Tetrazolium  
P   - Probability 
P<0.05  – Statistically significant at 5% level 
P>0.05  - Not statistically significant at 5% level 
p1    = proportion of cases (1st category) 
p2    = proportion of cases (2nd category) 
q1    = 1-p1 
q2    = 1-p2 
σ (sigma)  – Standard Deviation  
σ1   – Standard Deviation of the 1st category  
σ2   – Standard Deviation of the 2nd category 
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SE    – Standard Error of the mean  
(Standard Deviation / √n)  
Standard Error of Difference  
Between two Means  = √ [σ12/n1] + √ [σ22/n2] 
Standard error of difference  
between two proportions  =  √ [p1q1/n1+ p2q2/n2] 
UTI    – Urinary Tract Infection 
Z score for standard error  
of difference between  
two means = {Mean1- Mean2}/standard error of 
difference  
between two means 
Z score for standard error  
of difference between two  
proportions    = p1-p2/standard error of 
difference  
between two proportions 
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INTRODUCTION 
 Nitroblue tetrazolium test is one of the simplest and cost-effective  
methods in the assessment of neutrophil bactericidal function. This has also 
been used as a method of early diagnosis in bacterial infection. 
 Neutrophilic leucocytosis is considered as an indirect evidence of acute 
inflammation and acute infections though it is seen in several other conditions. 
To combat any infectious process, apart from the rise in leucocyte counts, a 
normal neutrophil function is also essential. 
 Patients with a neutrophilic response on exposure to infectious agents 
need not necessarily possess normal neutrophil functions like chemotaxis, 
phagocytosis, killing and degradation. 
 Diabetes mellitus is a common disease in which neutrophil functions are 
altered 1,2,3 
 A battery of tests are available to assess neutrophil functions which 
include NBT test, flow cytometry, spectrophotometric assays, chemotaxis 
assays, superoxide assays and immunoblotting4 which though accurate require 
expertise and monetary consideration while the NBT test is inexpensive and 
technically less demanding . 
 This prospective study focuses on the utility of NBT test to study 
neutrophil function in diabetics and to reiterate its role as a supplement in the 
diagnosis of bacterial infections.      
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AIMS AND OBJECTIVES 
1. To describe about the NBT test, its relation to bactericidal function of 
neutrophils and its scoring systems.  
2. To compare the NBT scores in non-diabetics with and without bacterial 
infection. 
3. To compare the NBT scores in diabetics with and without bacterial 
infection and show its usefulness in the assessment of response to infection 
in the diabetic population. 
4. To compare the difference in NBT scores between non-diabetics and 
diabetics without infection.   
5. To compare the difference in NBT scores between non-diabetics with 
infection and diabetics with infection and analyze if it could be related to 
the defective bactericidal function in diabetic patients. 
6. To observe the relationship between NBT score and absolute neutrophil 
count. 
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REVIEW OF LITERATURE 
 Peripheral blood leucocytes include neutrophils, eosinophils, basophils, 
lymphocytes and monocytes. The mature neutrophil measures 12-15µ in 
diameter. The cytoplasm is acidophilic with fine granules. The nucleus has 
clumped chromatin and has 2-5 distinct lobes separated by filaments which are 
narrow strands of dense heterochromatin.  Band cell is a granulocytic cell with 
a curved or coiled band shaped nucleus. Small number of band cells are seen in 
healthy subjects.   
Neutrophilia: Causes are numerous and common ones include acute infections, 
inflammation, intoxication, corticosteroid therapy, pregnancy and acute blood 
loss, among others. 
Neutrophilic granules: The neutrophilic granules4 serve as reservoirs for 
digestive and hydrolytic  enzymes. They are classified primary, secondary and 
tertiary granules. 
¾ Primary granules (azurophilic): The primary granules contain 
myeloperoxidase, neutral proteases which include elastase and 
cathepsins, protease inhibitors, acid hydrolases, acid phosphatase α 
mannosidase, N-acetyl glucosaminidase and cationic proteins. Azurophil 
granule proteins possess microbicidal activity and have a role in tissue 
destruction during inflammatory reaction. Myeloperoxidase reacts with 
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H2O2 and a halide to produce hypochlorous acid, a potent oxidant, 
believed to significantly contribute to the killing of microorganisms.  
¾ Secondary granules (specific): Proteins present in these granules include 
lysozyme, collagenase, vitamin B12 binding protein, heparanase and 
lactoferrin. Lysozyme hydrolyzes cell wall proteoglycan of some 
bacteria. Lactoferrin is necessary for hydroxyl radical formation and can 
influence the function of lysozyme to kill gram-negative bacteria. 
Heparanase helps in the extravasation of neutrophils. These granules’ 
membrane possess cytochrome b which regulates respiratory burst. 
¾ Tertiary granules: These contain gelatinase, FMLP receptor, 
cytochrome b, CD11b, CD18 and CD16 which are essential for cell 
adhesion. 
 Other granules are phosphosomes and secretory granules. 
Functions Of Neutrophils: 
 The neutrophils protect the host against pyogenic infections. The 
cellular events in acute inflammation include mobilization of neutrophils from 
marrow stores, adhesion and extravasation of the leucocytes, chemotaxis, 
leucocyte activation, phagocytosis, phagolysosome formation, respiratory burst 
and ultimately killing and degradation of the organisms4,5. 
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Bactericidal Mechanisms of neutrophils: 
 This includes oxidative and non-oxidative mechanisms of which the 
former is more important. Phagocytosis stimulates a burst in O2 consumption 
(respiratory burst), glycogenolysis, increased glucose oxidation via HMP shunt 
and production of reactive oxygen metabolites by the granules of activated 
neutrophils. The reactive oxygen species include superoxide anion(O2-), 
hydrogen peroxide(H2O2), hydroxyl radicals(OH•), hypochlorous acid (HOCl) 
and singlet oxygen. These reactive intermediates are generated by the NADPH 
oxidase, located on the plasma membrane which reduces molecular oxygen to 
O2-. The oxidase is quiescent in resting neutrophils and is stimulated following 
neutrophil activation.  
Synthesis of reactive oxygen intermediates: 
 
NADPH + 2O2                 NADP + 2 O2-+ H+ 
 
O2-  +  O2-  +  2H+                 H2O2  + O2 
 
           H202  +  Cl-       H20 +  OCl- 
NADPH oxidase 
Superoxide dismutase 
Myeloperoxidase 
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Neutrophil Function Tests 
1) Nitroblue tetrazolium test- assesses the respiratory burst activity. 
2) Flow cytometry using dihydrorhodamine 123 fluorescence (DHF)- 
measures respiratory burst leading to the production of reactive oxygen 
species. 
3) Flow cytometry to measure CD11/CD18 surface glycoproteins on 
neutrophils. 
4) Flow cytometry to measure L-selectin on neutrophils. 
5) Spectrophotometric assay to measure the cytochrome B content in an 
extract of detergent – disrupted neutrophils. 
6) Superoxide assays like chemiluminescence tests. 
7) Chemotaxis assays like polarization assay (studies the response of 
neutrophils to chemotactic factors) and the Rebuck skin window test. 
8) Quantitative ingestion assays (patient & control sera as opsonins). 
9) Myeloperoxidase staining and estimation. 
10) Immunoblotting- estimates cytochrome B subunit and cytosol oxidase 
component to differentiate X-linked from autosomal recessive forms of 
chronic granulomatous disease.4 
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Principle Of The NBT Reaction: 
 Under normal conditions, the enzyme NADPH oxidase in neutrophils is 
in an inactive state. During bacterial infections, phagocytosis of the microbes 
occur resulting in fusion of lysosome with phagosome and activation of 
NADPH oxidase. This enzyme is essential as mentioned earlier for production 
of oxygen derived free radicals.  
 Nitroblue tetrazolium is a colorless or yellow dye, which can penetrate 
the neutrophil cell membrane. If neutrophils are stimulated, NADPH oxidase 
converts the dye in the phagolysosome into blue black deposits called as 
formazan which can be observed under the microscope. In unstimulated 
conditions (like non-infectious states), most of the neutrophil oxidase is 
inactive and hence formazan formation on addition of NBT dye is less.6 
                        Activated NADPH oxidase 
NBT(yellow)        formazan (blue black deposit) 
Hence, the formation of formazan, is an indirect evidence to the degree 
of respiratory burst activity of neutrophils. 
Biological basis for increased NBT in infection: 
 McCall et al7, conducted NBT test along with other bactericidal indices 
like oxygen utilization and hexose monophosphate shunt activity. They 
observed significant elevations in bactericidal indices above that of controls, in 
all patients with elevated NBT scores. Thus it proved that increased 
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bactericidal capacity of neutrophils was the primary cause of increased NBT 
reduction.  
History of the NBT test: 
 The origin of NBT test dates back to 1967, when Baehner and Nathan8 
showed that while a small proportion of the neutrophils of normal subjects 
could invitro reduce the soluble dye to insoluble formazan precipitate, 
leucocytes from subjects with chronic granulomatous disease(CGD) were 
unable to effect this reaction, thus providing a sensitive diagnostic test for the 
diagnosis of the later condition. 
 In 1968 , Park, Fikrig and Smithwick9 described NBT as a rapid aid to 
the diagnosis of bacterial infection in children. Enhanced  NBT reduction was 
reported by Feigin et al10 (in systemic bacterial infections), Anderson et 
al11(malaria),Park et al9(systemic mycosis), Humbert et al12(new born infants) 
and in scarlet fever.13  
 Gordon et al6 , compared the NBT reduction scores between healthy 
volunteers and those with bacterial and viral infection and found significantly 
higher scores in NBT scores in bacterial infections compared to the latter. 
 Adnan et al 14 in 1972 showed that when skin of hamsters were 
experimentally infected with streptococci & staphylocci strains, an increase in 
percentage  and absolute number of NBT positive neutrophils occurred.  
 In cases with doubtful diagnosis of pulmonary thromboembolism and 
lobar pneumonia existed, the role of NBT was proved by Rowan et al15 in 
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1974, thus showing that NBT is useful to distinguish infective from non-
infective lesions. Similar results were obtained by Hellum KB et al16 in 1977. 
 An important application of NBT in rapid screening of neonatal 
infections/sepsis where a high NBT score correlated with the presence of 
infection was demonstrated by Dalens et al17 in 1981.  
 Though NBT test was useful in distinguishing bacterial from viral 
infections, Trojan et al18 observed that both early cases of bacterial meningitis 
and viral encephalitis had a low NBT score  in their blood samples. In contrary 
Kolmel et al19, studying granulocytes from CSF samples, observed higher NBT 
scores among bacterial meningitis patients compared with non-bacterial 
meningitis. 
 The effects of antibacterial drugs on NBT score was studied by Hellum 
KB et al20 in 1977 , who observed that there was a higher mean NBT score 
among the patients who had not received any antibacterial therapy compared 
with those who had received the treatment. Dalens et al17 showed that first few 
days of antibacterial treatment does not alter the NBT reduction. 
 Miller RM et al21 in 1976,observed enhanced  NBT reduction in febrile 
patients with bacterial infection compared to those febrile due to non-bacterial 
and non-infectious conditions. 
Infection And Diabetes Mellitus: 
 Some infections are more frequent in those with diabetes and some are 
more aggressive in the diabetic host.22 There are multiple defects in immunity 
in diabetes which explains the susceptibility to infection including impaired 
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neutrophil function.1-3 There are also other secondary causes such as frequent 
hospitalization, delayed wound healing and chronic renal failure.  
 Urinary Tract Infection(UTI) is more common in diabetes and about 
25% of diabetic women have asymptomatic bacteruria (four times the 
frequency in non-diabetic women). Asymptomatic bacteruria was observed 
among many cases in our study also. Escherichia coli is the most common 
pathogen. UTI in diabetes may be asymptomatic, or present with dysuria, 
increased frequency or urgency (lower UTI) or flank pain, fever and vomiting 
(upper UTI). 
 Respiratory tract infections may not be more frequent in diabetes, but 
bacteraemia, delayed resolution and recurrence are frequent.    
Common infections with increased incidence in Diabetic patients: 
a) Urinary tract infections 
b) Respiratory tract infections 
c) Soft tissue infections 
Infections predominantly occurring in diabetic patients: 
a) Malignant otitis externa 
b) Rhinocerebral mucormycosis 
c) Necrotizing fasciitis 
d) Fournier’s gangrene 
e) Emphysematous cholecystitis 
f) Emphysematous pyelonephritis; pyelitis and cystitis 
g) Infections in the diabetic foot. 
Predisposing Factors For Infections In Diabetes Mellius 
Primary factors: 
 Defects in the following functions of neutrophils 
¾ Adherence 
¾ Chemotaxis 
¾ Phagocytosis 
¾ Bactericidal activity  
 Myeloperoxidase deficiency 
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 Complement pathway defects 
 Cytokine-mediated(eg. Interleukin-1, tumor necrosis factor) 
Secondary factors: 
 Ketoacidosis 
 Intravascular access lines 
 Antibiotic misuse/resistance 
 Frequent hospitalization 
 Peripheral vascular disease 
 Neuropathy 
 Gastroparesis and aspiration 
 Indwelling urinary catheters 
 Chronic renal failure and dialysis 
 Total parenteral nutrition 
 
Neutrophil Dysfunctions In Diabetes Mellitus 
i) Adherence: 
 Peterson et al,23 observed that the neutrophils of patients with poorly 
controlled diabetes exhibited impaired adherence to a glass-wool column, and 
Bagdade24 showed an enhancement of adherence of neutrophils to a nylon-fiber 
column following an improvement in the control of blood glucose levels. 
Andersen et al25 showed similar results on examining the ability of neutrophils 
to bind to bovine aortic endothelium. 
ii) Mobilization and Chemotaxis: 
 There is reduced mobilization and chemotaxis of neutrophils in diabetes 
patients as shown by several investigators. 
 Using the Rebuck skin window technique26(an abrasion created on the 
volar forearm, and sterile coverslips being serially applied over several hours, 
and the coverslip smears stained) or its modification,1 researchers studied the 
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mobilization of neutrophils to the area of inflammation by microscopic 
examination of the stained smears over time. They found reduced mobilization 
in diabetes patients irrespective of whether diabetes was well controlled, poorly 
controlled or complicated by ketoacidosis. 
 A modified tissue-culture chamber method,27 where a chemotactic index 
was derived by comparing the original number of neutrophils with the number 
that had completely crossed a filter barrier in response to chemoattractants, also 
showed that neutrophils of patients with diabetes had a lower chemotactic 
index (i.e., diminished response), without any correlation with fasting blood 
glucose levels or type of therapy. Incubation of neutrophils of diabetics with 
insulin improved the chemotactic index.28 
Other techniques to study chemotaxis like subagarose technique29,30 also 
showed depressed chemotactic index in diabetics, which was correctable with 
intensive treatment of diabetes. 
iii) Phagocytosis: 
 Decreased phagocytosis, a feature of diabetes, was noted when washed 
neutrophils of poorly controlled diabetics and an equal number of 
Streptococcus pneumonia were incubated in 90% serum (phagocytosis being 
considered to be present if at least one bacterium was ingested). Incubation of 
neutrophils of diabetics with serum of healthy controls showed normal 
phagocytosis and incubation of control neutrophils in serum of diabetics 
chowed reduced phagocytosis. This suggested the possibility of an 
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opsonization defect affecting the neutrophils of diabetics as supported later by 
the works of Rayfield et al31 and Davidson et al32. 
 Using the lysostaphin assay technique, which allows differentiation 
between phagocytosis and intra-cellular killing, Tan et al33 demonstrated a 
defect in phagocytosis of Staphylococcus aureus in diabetics, which showed no 
correlation with the level of glycemic control or history of recurrent infections. 
 Alexiewicz et al34 demonstrated an inverse relationship between 
phagocytic activity and fasting glucose levels, as well as a reduced phagocytic 
function. 
 Defects in adherence and phagocytosis did not correlate with levels of 
glycosylated hemoglobin (HbA1c).25,32 
iv) Bactericidal activity: 
 Early studies such as that of Dziatkowiak et al,35 compared the number 
of live Staphylococcus aureus in a granulocyte with the total number engulfed , 
to calculate the proportion of organisms killed. 
 Studies using single low ratio of bacteria to neutrophils, demonstrated 
diminished killing by the neutrophils of the patients with diabetes while others 
did not.28 Repine et al,36 used five different ratios of bacteria to neutrophils. 
Study patients included infected and non-infected individuals with and without 
diabetes. Cells were incubated with Staphylococcus aureus  for one hour after 
which colonies were counted. The rates of intracellular killing of bacteria by 
the neutrophils from uninfected controls and by the neutrophils of persons with 
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well controlled diabetes were comparable. Neutrophils from uninfected patients 
with poorly controlled diabetes functioned less well, especially when the higher 
ratios of bacteria to the neutrophils were used. Although the bactericidal 
activity of neutrophils from infected patients with well controlled diabetes was 
similar to that of uninfected controls, they did not display the increase in killing 
activity seen in neutrophils of infected patients without diabetes. The 
bactericidal function of neutrophils from infected patients with poorly 
controlled diabetes was the lowest of all groups.   
 Production of superoxide anions and other oxygen derived free radicals 
during respiratory burst by stimulated neutrophils produce chemiluminiscence, 
which was studied by Shah et al37 using neutrophils from patients with diabetes 
and controls. In resting neutrophils the chemiluminescence of cells was 
comparable in both groups. But on stimulation, the neutrophils from patients 
with diabetes showed a blunted response with regard to superoxide production 
and chemiluminescence. The control of diabetes improved 
chemiluminescence38 and also other neutrophil functions.36, 39 Cross incubation 
serum studies effected no change, suggesting that an intracellular defect rather 
than an inhibitory serum factor might have been present. Whether this 
bactericidal defect in diabetes is a predisposing factor for infections is 
uncertain, as the defect is seen in diabetes, irrespective of whether they have 
had recurrent/serious infections.40   
 Li.Y.M.41 suggested that advanced glycation end products (AGEs) 
associated with diabetes may bind to specific motifs common to lactoferrin, 
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lysozyme and other antimicrobial proteins found in neutrophils and interfere 
with antimicrobial function of these host defence molecules. 
v) Other mechanisms for neutrophil defects in diabetes: 
 These include a state of persistent low level activation of the neutrophils 
by AGEs. This is evidenced by an increased concentration of neutrophil 
elastase, increased activity of neutrophil alkaline phosphatase and an increased 
rate of neutrophil oxygen consumption among unstimulated neutrophils of 
patients with diabetes. This hyperexcited state leads to spontaneous activation 
of the respiratory burst and release of neutrophil granule components that can 
be detrimental in two ways: 
a) It may lead to ‘burnt out’ of neutrophils that respond less 
vigorously when stimulated by an infectious pathogen. 
b) It may initiate pathological processes leading to vascular injury42 
NBT test in diabetes mellitus: 
 Relatively a few authors have done works using NBT test in diabetes 
mellitus. 
 Kruszewski et al43 in 1979 studied 44 diabetic patients and found normal 
range of NBT scores in those without infection and significantly higher values 
in those with bacterial infection. 
 Lechowski et al44 in 1991 observed that the NBT reducing value of 
circulating phagocytes in diabetic dogs was increased (P less than 0.05), 
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whereas in these cells increase in NBT reduction following stimulation was 
decreased (P less than 0.05). It is suggested that in diabetic dogs changes in 
activity of circulating and tissue phagocytes may occur. 
 Nurun Nabi et al45 in 2005 studied neutrophil dysfunction in 
streptozocin induced type1 diabetic rats and found that diabetic rats showed 
higher NBT reduction than controls which correlated with polarization assay in 
which the neutrophils of diabetic rats were significantly more polarized at 
baseline level compared to control rats.   
 Larijani et al46 in 2007 compared the effect of NBT between type2 
diabetes patients and healthy controls. They found that NBT test was 
significantly high in diabetics compared to controls. But stimulation(by 
endotoxin) resulted in inadequate rise of NBT score compared to controls.  
Other applications of the NBT test: 
 NBT test is an useful indicator of infection in patients with underlying 
cancer. This was shown by Lehane et al47 who observed that cancer patients 
with infection showed a significantly higher score than those without infection. 
Similar results were demonstrated by Jadrezejczak et al.48 
 Jedrzejczak et al49 compared the NBT scores between untreated cancer 
patients with or without bacterial infection and those on radiotherapy and/or 
chemotherapy. NBT scores were raised in cancer patients with bacterial 
infection irrespective of treatment. Thus the NBT test was an useful tool for 
infection screening in cancer patients. However the test could not be done in 
severe neutropenia 
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 Patients with sickle cell anemia have an increased susceptibility to 
bacterial infections. There are differing opinions by different researchers. 
Walter et al50 found a significant difference in the mean NBT values between 
sickle cell anemia patients with bacterial infection and those without infection, 
whereas Wajima T51 observed low NBT scores in sickle cell patients in painful 
crisis with bacterial infection. Akinyanju52 had similar results as that of Walter 
et al except that he found low scores in painful crisis (similar to Wajima) and 
early osteomyelitis in sickle patients. 
 Wantzin53 observed a negative effect of prednisolone on the NBT 
response as seen in both non-stimulated and stimulated NBT tests despite the 
fact that a pronounced neutrophil granulocytosis occurred on stimulation with 
toxins in the stimulated test groups. The percentage of NBT stained neutrophils 
and absolute count of NBT stained neutrophils were reduced. 
 Hypertriglyceridemia depresses the granulocytic activity as was 
demonstrated by Broden et al.54 He observed that significant number of 
patients with acute bacterial pancreatitis, despite having fever, granulocytosis 
and elevated ESR had a lower than normal NBT scores. 
 Normal pregnant women have NBT scores similar to that of healthy 
volunteers.10 
 Comparison of NBT scores with total leucocyte count, differential 
leucocyte count, ESR and neutrophil alkaline phosphatase (NAP) scores was 
conducted by Douwes et al.55 In bacterial infection, the NBT scores were 
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significantly raised, whereas such a rise was not observed with the TLC, ESR 
or LAP scores. 
 Kucharska et al56 studied NBT test in bacterial and viral meningitis. 
They found a significantly higher  NBT reduction in neutrophils of  bacterial 
compared to viral meningitis, whereas NBT scores in monocytes/macrophages 
were raised in both types of meningitis.    
Other factors which affect the NBT scores:    
 Earlier, when heparin was used as the anticoagulant, it was observed that 
higher concentrations of it resulted in falsely high NBT scores 57,58. Also, 
experiments comparing EDTA and heparin have shown that while formazan 
staining was satisfactory with the latter, cell definition was relatively poor with 
cell destruction and clumping rendering counting difficult.                
Extravasation of formazan from neutrophils has been seen in EDTA 
anticoagulated blood. The use of Ficoll sucrose polymer in the NBT reagent 
was found to prevent this leak by effecting membrane stabilization6. 
 Time lag between blood collection and the performance of the test 
resulted in falsely higher NBT scores57. The mean NBT scores increased when 
blood samples were kept at room temperature for more than 2 hours, but 
remained virtually constant until 12 hours when stored at 4°C. After 12 hours 
the mean NBT scores fell slightly at both temperatures.60  
 The effects of pH, composition of the buffer used, and NBT dye 
concentration have also been  investigated. Phosphate-buffer with a pH of 7.2 
containing 0-1% NBT dye gave the most reliable results 57,59,60. Both resting 
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and stimulated neutrophils showed an increase in NBT positivity with higher 
concentrations of NBT dye.6  
 NBT scores increase with increasing incubation time. In resting 
neutrophils a 20 min incubation at 37°C resulted in a mean NBT score of 10% 
whereas a period of 30 min gave a score of 20%.60 As cell destruction and 
clumping enhanced with higher incubation times, 30 min incubation at 37C 
followed by 15 min at room temperature has been considered as optimal.61  
 Presence of specific antibodies and complements in serum have been 
shown to raise the NBT scores62. 
 Differences in counting techniques of NBT positive neutrophils has 
been an important reason for variations in results between workers.59  
 In view of the fact that various factors and conditions alter the NBT test 
results, the scores should be interpreted with caution and in the context of other 
laboratory test results and clinical picture of the patient.63 
Various methods/modifications of performing the NBT test: 
a) The spontaneous NBT test is one were the neutrophils’ response to the 
addition of NBT dye is studied without the addition of any external 
stimulants. Instead of whole blood, the use of buffy coat preparation has 
the advantage of performing the test even in the presence of neutropenia 
and does not impair the cytological quality of preparation.6  
b)  The stimulated NBT test is one were the neutrophils from the same 
subjects are stimulated in vitro by adding endotoxin, and the rise in 
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percentage of cells reducing NBT determined.64 In certain situations 
(usually when a very low or completely negative result is obtained by 
the spontaneous test), it is necessary to perform the stimulated test in 
order to differentiate a transient lack of responsiveness from a 
congenital defect. A good example of the former might be a patient on 
high dose of corticosteroids and of the latter the classic example is 
chronic granulomatous disease.65,66  
c) The cytocentrifuge NBT test is a modification of the technique were the 
anticoagulated whole blood is dissolved with the NBT reagent and 
hemolysed. The hemolysate is then cytocentrifuged and smears are spun 
on to glass slides. This method reduces the risk of non-specific 
stimulation of neutrophils and also bypasses cell membrane disruption 
which could occur when subjected to the lateral shear involved in 
manual smearing.60  
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MATERIALS AND METHODS 
 This prospective study was conducted in the Goschen Institute of 
Pathology, Madras Medical College, from 2006-2008. The study included 127 
subjects divided into 4 categories. 31 were non-diabetics without bacterial 
infection (c), 31 were non-diabetic patients with a clinical diagnosis of bacterial 
infection (i), 33 patients had diabetes (d) with no bacterial infection 
(asymptomatic infections like UTI excluded by urine culture).and 32 patients  
had diabetes and bacterial infection (di). An attempt had been made to select 
patients with similar infections in non diabetics (i) and diabetics (di). 
Inclusion Criteria: The bacterial infection was confirmed by bacteriological 
isolation through culture or other relevant tests. The selected diabetic study 
population had diabetes for at least 2 years duration, with or without treatment. 
Exclusion Criteria: The following were excluded from the study population  
1) Patients with subclinical infection  
2) Patients who had completed a full course of antibiotics 
3) Patients in convalescence 
 4) Duration of diabetes of <2 years.  
 The study population were subjected to the lab investigations which 
included total leucocyte count(normal range of total leucocyte count : 4.0-10.0x 
109 /L), differential leucocyte count(normal: neutrophils40-80%; 
lymphocytes:20-40%; monocytes:2-10%; eosinophils:1-6%; and basophils1-
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2%), erythrocyte sedimentation rate (normal range for males:1-25mm/hr; for 
females:0-17mm/hr), fasting blood sugar (normal range :75-115mg/dl; fasting 
levels in diabetes mellitus: >125mg/dl)67  and bacteriological tests and NBT 
test. Absolute neutrophil count (ANC) was derived from TLC and DLC 
(normal ANC=  2.0-7.0x 109/L i.e.,40%-80% of total leucocyte count)68-70. 
NBT Test Procedure  
Reagents : 
• Solution A: 0.2 M Monobasic sodium phosphate (31.2g 
aH2PO4.2H2O/Litre) 
• Solution B: 0.2 M Dibasic sodium phosphate (28.3g Na2HPO4/Litre) 
• Deionized water 
• Nitroblue tetrazolium dye (crystalline grade III, Sigma chemical 
company) 
• Aqueous safranin 0.5%  
Preparation of NBT Solution: 
 To 20ml of solution A,  80ml of solution B was added. This solution 
was dissolved in 100ml deionized water, forming the working buffer with a 
final pH of 7.2 . NBT dye was dissolved at a concentration of 0.2% to the 
working buffer, and stored at 40C. 
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 The method followed in this study was a modification of that of Gordon 
et al.6 4ml venous blood was collected in EDTA (2mg/ml of blood) bottles, 
from each subject and transferred to plastic tubes, centrifuged at 3000rpm for 8 
minutes. The separated buffy coat was transferred using plastic pipettes into 
separate plastic tubes. Equal amount of NBT solution was added , mixed gently 
and incubated at 370C for 30 minutes and left at room temperature for 15 
minutes. The mixture was mixed again gently, a drop of which was smeared on 
a glass slide, dried, heat fixed and counterstained with safranin for 2 minutes 
that stains the nucleus of leucocytes red. The smears were them washed and left 
to dry.  
Counting techniques: 
 The slides were examined under oil immersion objective (1000x) and 
100 neutrophils (identified by the number of nuclear lobes) were observed 
sequentially. 
 The NBT scoring was done by two scoring systems:  
  (A) 1st (Classic) scoring system 
  (B) 2nd (Grading) system 
(i) In the first scoring system (classic system), the cells exhibiting discrete 
fine/coarse particulate cytoplasmic distribution of formazan as 
blue/black granules, in addition to dense deposits of formazan6 were 
counted as NBT positive cells. Those cells which showed no formazan 
deposits were counted as NBT negative.The number or nature of  
formazan granules was not taken into consideration. The NBT score was 
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expressed in percentage. Only neutrophils with intact cell membranes 
were taken for observation. 
 NBT score in healthy volunteers (range) in our study: 6-25% 
(ii) In the second scoring system (grading system) Grading of the number 
and nature of formazan granules in NBT stained neutrophils was 
attempted similar to that of NAP ( Neutrophil alkaline phosphatase) 
scoring.71 The intensity of the reaction  in neutrophils varies from 
negative to strongly positive with fine/coarse granules filling the 
cytoplasm and overlying the nucleus. An overall score is obtained by 
assessing the stain intensity in 100 consecutive neutrophils, with each 
neutrophil scored on a scale of 0-4 as follows: 
 0  - Negative, no granules 
 1 - Occasional granules scattered in the cytoplasm  
 2  - Moderate number of granules <25% of cytoplasm 
 3  - Numerous granules occupying < 50% cytoplasm 
4 - Heavy positivity with numerous coarse granules crowding  
the  cytoplasm, frequently overlying the nucleus  > 50% 
of cytoplasm 
The overall possible score will range between 0 and 400 per 100 cells.   
The NBT grading score in healthy volunteers in our study : 12-167. 
The NBT scores and the Absolute neutrophil counts of the 4 study 
groups were compared and results tabulated and statistical analysis done using 
the Z test. 
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NBT dye with buffer solution   Buffy coat after centrifuging 
 
 
 
 
 
Buffy coat with NBT –buffer        Buffy coat with NBT-buffer mixture 
 mixture prior to incubation            after incubation, turning blue 
 
 34
 
Peripheral smear showing neutrophilia, with neutrophils exhibiting toxic 
granules(1000x) 
 
 
 
 
 
 
Peripheral blood buffy coat smear, NBT stain (1000x) showing NBT (Blue 
black granules / deposits) positive neutrophils (        ) and a NBT negative 
neutrophil (        ) 
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Peripheral blood buffy coat smear, NBT stain (1000x) showing a positively 
stained neutrophil (1 grade) (        ) and a NBT negative neutrophil (        ) 
 
 
Peripheral blood buffy coat smear, NBT stain (1000x) showing several 
NBT stained neutrophils  (0 grade         ), (1+ grade        )  
(2+ grade      ) (3+ grade       ) and (4+ grade        ) 
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RESULTS 
A. Results of NBT scoring based on the 1st (Classic) Scoring System 
Table 1  : Experimental categories 
Category Nomenclature n 
Non-diabetics without bacterial infection c 31 
Non-diabetics with bacterial infection i 31 
Diabetics without bacterial infection d 33 
Diabetics with bacterial infection di 32 
 
Non-diabetics without infection (C): 
 This group (c) of 31 subjects in our study, consisted of 17 males and 14 
females. The age range of this group was 18 to 41 years, with a median of 20 
years. All were healthy with no signs and symptoms of diabetes or infection. 
 The mean NBT score for this group was 21.8% (confidence interval of 
21.8+/-5). 
 There was no significant difference (P>0.05) in the mean NBT scores 
between the males (20.6%) and females (23.3%).  
 The mean absolute neutrophil count (ANC) was 4.3x109/L. 
 The results are summarised in Table 2.             
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Table 2 
n Mean NBT % 
NBT Confidence 
Interval 
(Mean+/-2SE)) 
Mean 
ANC(x109/L.) 
ANC 
Confidence 
Interval 
(Mean+/-
2SE) 
31 21.8 21.8+/-5 4.3 4.3+/-0.676
 
Non-Diabetics with Infection (i) : 
 31 patients in our study had a clinically and microbiologically proved 
bacterial infection of which 24 were males and 7 females with their age ranging 
from 19 to 75 years. The distribution of cases are tabulated below. 
Table 3 
Diagnosis n 
Wound infection 11 
Abscess 3 
Respiratory infection 3 
Ulcer foot 3 
Urinary tract infection 2 
Leptospirosis 2 
Enteric fever 2 
Fournier’s gangrene 1 
Necrotizing fasciitis 1 
Meningoencephalitis 1 
Septicemia 1 
Vaginitis 1 
TOTAL 31 
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The mean NBT score in this category (i) was 76.5% with a confidence 
interval of 76.5+/-6.4.  
The mean NBT score in males was 76.9%  and females was 75.1% with 
no significant difference(P>0.05). 
The mean ANC was 6.1x109/L.The results of summarised in Table 4. 
Table 4   
n Mean NBT % 
NBT 
Confidence 
Interval 
(Mean+/-2SE)) 
Mean ANC 
(x109/L.) 
ANC 
Confidence 
Interval 
(Mean+/-2SE) 
31 76.5 76.5+/-6.4 6.1 6.1+/-1.61 
                                  
Diabetes without Infection (d): 
33 diabetic patients without infection were selected of whom 16 were 
males and 17 were females in the age range of 27 to 78 years.  
The mean NBT score in this group was 32.7% with 95% of the scores 
falling between 25.3% and 40.1% .  
The mean NBT score of the males was 26.06% and females was 39% 
with no significant difference (P>0.05) between them. 
The mean ANC was 4.6x109/L. The results are summarised in Table 5.  
24 cases had FBS<200mg/dl whereas the rest had higher fasting sugar 
levels. 
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Table 5 
n Mean NBT % 
NBT 
Confidence 
Interval 
(Mean+/-2SE))
Mean ANC 
(x109/L.) 
ANC 
Confidence 
Interval 
(Mean+/-2SE) 
33 32.7 32.7+/-7.4 4.6 4.6+/-0.528 
 
Diabetes with Infection (di):  
This category of 32 patients had diabetes and bacterial infection of 
which 19 were males and 17 females, with age ranging from 20 to 85 years. 
The distribution of cases are listed in Table 6.  
Table 6  
Diagnosis Number of cases 
Diabetic foot 16 
Urinary tract infection 11 
Wound infection 1 
Melioidosis 1 
Peritonitis 1 
Enteric fever 1 
Osteomyelitis 1 
TOTAL 32 
 
 The mean NBT score in (di) group was 63.4% with 95% of the scores 
between 55.6%  and 71.2% 
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 The mean NBT of the males was 59% and not significantly lower than 
that of females (mean NBT=69.8%). 
The mean ANC was 7.6x109/L 
The results are summarised Table 7.    
Table7    
n Mean NBT % 
NBT Confidence 
Interval  
(Mean+/-2SE)) 
Mean ANC 
(x109/L.) 
ANC 
Confidence 
Interval 
(Mean+/-
2SE) 
32 63.4% 63.4+/-7.8 7.6 7.6+/-1.676 
 
Table 8 
Case (n) distribution in 1st (classic) scoring system 
NBT score range c i d di 
0-20 19 0 8 1 
21-40 9 2 18 6 
41-60 2 4 3 8 
61-80 1 11 2 6 
81-100 0 14 2 11 
Total (n) 31 31 33 32 
 
 In this classic system, as expected, more number of non-diabetics 
without infection (19 cases) had their scores less than 20, the diabetics without 
infection (18 cases) between 21-40, the diabetics with infection (20 cases) 
between 21-80, while most non-diabetics with infection (25 cases) had  scores 
between 61-100. 
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Comparison of Results of the 4 Groups  
Comparison of  the results of non-diabetics without (c) and with 
infection(i) : 
Table 9  
Comparison of NBT scores  
 Mean NBT (%) σ 
Standard 
error of 
difference 
between 2 
means 
Z 
score P value
Non-diabetics without 
infection (c) 
21.8 14 
Non-diabetics with 
Infection(i) 
76.5 17.7 
4.0 13.495 <0.05 
 
Table 10:  
Comparison of ANCs   
 Mean ANC σ 
Standard 
error of 
difference 
between 2 
means 
Z 
score 
P 
value 
Non-diabetics without 
infection (c) 4.3 x10
9/L 1.9 
Non-diabetics with 
Infection(i) 6.1 x109/L 4.5 
878 1.992 <0.05 
 
The mean NBT scores of non-diabetics with infection (i) was 76.5% and 
was found to be significantly higher than that of non-diabetics without 
infection (21.8%). As expected, the neutrophil count was higher among those 
with bacterial infection than controls.  
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Figure 1 : Comparison of NBT scores in non-diabetics without (c) and with 
infection (i) 
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Figure 2 Comparison of ANC in non-diabetics without (c) and with  
infection (i) 
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Figure 3 Scatter diagram comparing NBT and ANC in non-diabetics without 
infection 
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From the scatter diagram above it could be seen that with an increase in 
ANC there was no significant rise in NBT scores. 
Figure 4  Scatter diagram comparing NBT and ANC in non-diabetics with 
infection 
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 From the diagram above, as was expected, in the presence of infection 
there was an  increase in NBT score with an increase in ANC - reflection of a 
normal neutrophil functional response.  
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The Comparison of diabetics without (d) and with infection (di): 
Table 11:  
Comparison of NBT scores   
 
Mean 
NBT 
(%) 
σ 
Standard 
error of 
difference 
between 2 
means 
Z 
score 
P 
value 
Diabetics without infection (d) 32.7 20.9 
Diabetics with infection (di) 63.4 21.8 
5.3 5.792 <0.05 
  
Table 12 
Comparison of ANCs 
 
Mean 
ANC 
σ 
Standard 
error of 
difference 
between 2 
means 
Z score 
P 
value 
Diabetics without 
Infection(d) 
4.6 x109/L 1.5 
Diabetics with 
infection(di) 
7.6 x109/L 4.7 
870 3.486 <0.05 
 
 As shown in above the mean NBT scores and ANC of diabetics with 
infection (di) was significantly higher than diabetics without infection(d). 
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Figure 5 : Comparison of NBT scores in diabetics without (d) and with (di) 
infection  
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Figure 6 : Comparison of ANCs in diabetics without (d) and with (di) 
infections  
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Figure 7. Scatter diagram comparing NBT and ANC in diabetics without 
infection 
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 From this diagram it was observed that with an increase in ANC, there 
was an increased NBT score.  
Figure 8. Scatter diagram comparing NBT and ANC in diabetics with infection 
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 From this table it is observed that with increasing neutrophil counts 
there is a decrease in NBT scores, probably a reflection of premature  
exhaustion and consequent impaired neutrophil function in diabetic patients 
with infection.  
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Comparing of non-diabetics (c) and diabetic(d) without infection : 
Table 13 Comparing the NBT scores 
 
Mean 
NBT 
(%) 
σ 
Standard 
error of 
difference 
between 2 
means 
Z score P value 
Non-diabetics  
without infection (c) 
21.8 14 
Diabetics without 
infection (d) 
32.7 20.9
4.4 2.465 <0.05 
 
 As shown above the mean NBT scores of diabetes without infection(d) 
was 32.7% and was significantly higher (P<0.05) than that of non-diabetics 
without infection(21.8%) . 
Table 14  Comparing of ANCs 
 
Mean 
ANC σ 
Standard error 
of difference 
between 2 
means 
Z 
score 
P 
value 
Non-diabetics 
without infection 
(c) 
4.3 
x109/L 
1.9 
Diabetics without 
infection (d) 
4.6 
x109/L 
1.5 
430 0.637 >0.05 
  
However no significant difference was found between their mean ANCs. 
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Figure 9 : Comparison of NBT scores in nondiabetics (c) and diabetics (d) 
without infection  
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Figure 10 : Comparison of ANCs scores in nondiabetics (c) and diabetics (d) 
without infection 
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Comparison of non-diabetics (i) and diabetics(di) with infection : 
Table  15 Comparison of  NBT scores 
 Mean NBT (%) σ 
Standard 
error of 
difference 
between 2 
means 
Z score P value 
Non-diabetics with 
infection(i) 76.5 17.7 
Diabetics with 
infection(di) 63.4 21.8 
4.9 2.622 <0.05 
 
 The mean NBT in diabetics with infection is significantly lower than 
that of non-diabetics with infection (P<0.05). 
Table 16 Comparison of ANC 
 Mean ANC σ 
Standard 
error of 
difference 
between 2 
means 
Z 
score P value 
Non-diabetics with 
infection(i) 
6.1 x109/L 4.5 
Diabetics with 
infection(di) 
7.6 x109/L 4.7 
1160 1.342 >0.05 
 
 From the above two tables, it is seen that though the diabetics with 
infection (di) have a lower NBT score compared to non-diabetics with infection 
(i), they have  a slightly higher (though not significant) mean ANC compared 
to the latter. This higher mean ANC in diabetics with infection (di) is probably 
a reflection of a compensatory increase to a compromised neutrophil function .  
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Figure 11 : Comparison of NBT scores in non-diabetics (i) and diabetics (di) 
with infection 
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Figure 12 : Comparison of ANCs in non-diabetics (i) and diabetics (di) with 
infection  
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B. Results of NBT scoring based on the 2nd (grading) scoring system:  
 The range and mean values for each of the four categories were: non-
diabetics without infection 12-167 (mean 82); non-diabetics with infection 48-
348 (mean 228.5); diabetics without infection 51-260 (mean 117.2); diabetics 
with infection 106-311(mean 198.8) which are given in Table 17. 
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Table 17 Mean NBT scores based on the grading (2nd scoring) system 
 Non-diabetics 
without 
infection (c) 
Non-diabetics 
with infection 
(i) 
Diabetics 
without 
infection (d) 
Diabetics 
with 
infection (di)
Mean 
score 
82 228.5 117.2 198.8 
 
From the above table it was observed that the mean NBT scores of non-
diabetics with infection (i) was higher (P<0.05) than that of non-diabetics 
without infection (c). the mean NBT score of diabetics was higher (P<0.05) in 
those with infection (di) compared to those without infection (d). In those 
without infection, the mean NBT score was higher (P<0.05) in diabetics (d) 
compared to non-diabetics (c). And finally, among  those with infection the 
score was higher in non-diabetics (i) compared to diabetics (di).   
Table 18 
 Case (n) distribution in NBT Grading system 
NBT Score 
range C i d di 
0-50 11 1 0 0 
51-100 7 1 15 0 
101-150 7 2 11 10 
151-200 3 5 4 7 
201-250 0 9 2 7 
251-300 0 8 1 5 
301-350 0 4 0 2 
351-400 0 0 0 0 
Total (n) 28 30 33 31 
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 In this grading system also, the highest score ranges in the various 
categories were: non-diabetics without infection (11 cases) 0- 50, the diabetics 
without infection (15 cases) between 51-100, the diabetics with infection (10 
cases) between 101-150 while most non-diabetics with infection (17 cases) had  
scores between 200-300. Hence, we observe in this scoring system (similar to 
the first), that though higher scores are obtained in most cases of infection, 
cases of diabetes with infection had relatively lesser scores compared with non-
diabetics with infection.  
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DISCUSSION 
 Till date the utility of NBT test had been in the diagnosis of chronic 
granulomatous disease (CGD). Being technically simple and fairly economical, 
an attempt has been made to extrapolate this test’s usefulness in detecting and 
quantifying neutrophil function in patients with diabetes mellitus.   
Comparison with standard studies between non-diabetics with (i) and 
without (c) infection 
 Table 19 Comparison of mean NBT scores (classic scoring system).  
Study Mean NBT% 
(i) 
Mean NBT% 
(c) 
P value 
Gordon et al6 1973 34.2 6.1 <0.05 
Gordon et al72 1974 21 5 <0.05 
Gordon et al60 1975 60 18 <0.05 
Trojan et al13 1975 72 33 <0.05 
Bjorksten et al731975 19 13 <0.05 
Hellum KB20 1977 29.8 5.3 <0.05 
Yun Woong Ko et al74 1977 10.6 3.2 <0.05 
Akinyanju et al52 1985 41 20 <0.05 
Present study 76.5 21.8 <0.05 
 
Table 20  Comparison of mean ANC   
Study  Mean ANC (i) Mean ANC (c) 
Yun Woong Ko et al 1977 10.4 x109/L 4 x109/L 
Present study 6.1 x109/L 4.3 x109/L 
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 The significant difference in the mean NBT scores between non-
diabetics with infection (76.5%) and non-diabetics without infection (21.8%), 
obtained in our study was similar to that of various standard studies as shown 
in the table 19. But some studies showed lower NBT scores which might be 
due to differences in procedure and sample size. With reference to counting 
techniques, some studies6 considered only those cells exhibiting a discrete 
particulate cytoplasmic distribution of formazan along with those showing 
dense deposits of formazan (block positivity) as positive cells whereas in our 
study both fine & coarse granules and dense deposits were taken as positive.  
 This rise in NBT scores seen in the presence of infection in our study as 
with others, was in accordance to the fact that neutrophils, on stimulation by an 
infectious pathogen, have an increased bactericidal activity.7 Similarly as 
shown in table 20, a significant difference in mean ANCs between nondiabetics 
without and with infection was found in the standard study as in ours. 
Comparison with a standard study between diabetics without  (d) and with 
(di) infection  
Table 21 Comparison of NBT scores and ANC 
  Yun Woong 
Ko et al 1977 
Present 
study 
No. of cases 10 33 
Mean NBT % 2.6 32.7 
Diabetics without 
infection (d) 
Mean ANC x109/L 3.5 4.6 
No. of cases 10 32 
Mean NBT% 4.6 63.4 
Diabetics with 
infection (di) 
Mean ANC x109/L 9.9 7.6 
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 As shown in the table above  the mean NBT scores and ANC of 
diabetics with infection(di) was significantly higher than diabetics without 
infection(d) in our study. In the study by Yun Woong Ko et al74, although the 
mean NBT was higher in diabetics with infection it was not statistically 
significant probably due to a small sample size . The diabetics with infection in 
our study were able to increase their neutrophil counts as well as the respiratory 
burst activity (higher NBT score). 
Irrespective of the state of diabetes, our study confers that mean NBT 
and ANC were significantly higher in patients with infection. 
Comparison with a standard study between non-diabetics (c) and diabetics 
(d) without infection: 
On comparing the mean NBT scores of the diabetics and the non-
diabetics without infection   categories of our study with that of other standard 
studies,  our results ,i.e.,  a higher basal mean NBT score in diabetics,compared 
well with those of  Kruszewski et al43 in 1979 , Lechowski et al44 in 1991 and 
Larijani et al46 in 2007 but not with Yun Woong Ko et al74 which might be due 
to a small sample size.    
Table 22 Comparison of NBT scores and ANC  
  Yun Woong Ko et al 1977 
Present 
study 
No. of cases 27 31 
Mean NBT 3.2 21.8 
Non-diabetics without  
infection (c) 
Mean ANC 4 4.3 
No. of cases 10 33 
Mean NBT 2.6 32.7 
Diabetics without infection (d) 
Mean ANC 3.5 4.6 
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 The higher mean NBT score in diabetics (d) compared to the non-
diabetics without infection (c) could be related to the persistent activated state 
of neutrophils seen in diabetics due to AGEs42. Nuran Nabi et al45 in 2005 ,  
also found that diabetic rats showed higher NBT scores compared to control 
healthy rats (P<0.001) which was comparable to other neutrophil function tests 
like polarization assay where the neutrophils of diabetic rats were more 
polarized at baseline level compared to control rats.   
Comparison with standard study between non-diabetics (i) and diabetics 
(di) with infection  
Table 23 Comparison of NBT scores and ANC 
  Yun Woong 
Ko et al 1977 
Present 
study 
No. of cases 10 31 
Mean NBT % 10.6 76.5 
Non-diabetics with 
Infection (i) 
Mean ANC x109/L 10.4 6.1 
No. of cases 10 32 
Mean NBT% 4.6 63.4 
Diabetes with 
infection (di) 
Mean ANC x109/L 9.9 7.6 
 
 Despite the presence or absence of diabetes, both the groups with 
infection (di, i) had significantly high NBT scores and mean ANCs compared 
to their non-infected counterparts(d,c) respectively, but the mean NBT scores 
of diabetics with infection(63.4%) did not reach the high mean NBT scores of 
non-diabetics with infection(76.5%). This difference was significant (P<0.05).  
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Our results were in concurrence with the standard study  by Larijani et 
al46 in 2007, who compared 19 diabetic foot patients with 20 controls. The 
mean NBT scores of the non-infected diabetics in their study was significantly 
higher compared to controls, whereas stimulated NBT test  showed an 
inadequate rise in diabetics but a marked rise in controls.   
It could probably be related to the fact that the persistent hyper-excited 
state of neutrophils in diabetics leads to ‘burn-out’ of neutrophils which 
respond inadequately when stimulated by an infectious pathogen. This burnt-
out state had been demonstrated by Shah et al,37 who showed reduced 
superoxide radical production by neutrophils of diabetics on exposure to 
infecting pathogen. The production of superoxide and other free radicals 
require NADPH-oxidase which is also essential for NBT reduction. Hence the 
constant state of activation of neutrophils in resting state in diabetics could 
probably also result in loss of enzymes  necessary for oxygen derived free 
radical production, when stimulated by infectious pathogens leading to a 
inadequate functional response ( NBT score).46 
 Binding of advanced glycation end products (AGEs) to lysosomal 
enzymes as was demonstrated by Li.Y.M41 could also play a role in the reduced 
elevation of respiratory burst.   
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Comparing the two NBT scoring systems 
Table 24 : Percentage of case distribution in 1st (classic) scoring system 
S.No. NBT  score range c (%) i (%) d (%) di (%) 
1 0-20 61.3 0 24.2 3.1 
2 21-40 29 6.4 54.5 18.8 
3 41-60 6.5 12.9 9.1 25 
4 61-80 3.2 35.5 6.1 18.7 
5 81-100 0 45.2 6.1 34.4 
  Total % 100 100 100 100 
 
Table 25 : Percentage of case distribution in 2nd (Grading) system 
S.No. 
NBT score 
range c (%) i (%) d (%) di (%)
1 0-50 39.3 3.3 0 0 
2 51-100 25 3.3 45.5 0 
3 101-150 25 6.7 33.3 32.3 
4 151-200 10.7 16.7 12.1 22.6 
5 201-250 0 30 6.1 22.6 
6 251-300 0 26.7 3 16.1 
7 301-350 0 13.3 0 6.4 
8 351-400 0 0 0 0 
 Total % 100 100 100 100 
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Figure 13 : Percentage case distribution (1st scoring system) 
 
 
Figure 14: Percentage case distribution (2nd scoring system) 
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Table 26 : Comparison of the two scoring systems based on the difference in 
proportion of cases 
c Vs d Score range 
Categories 
compared 
Standard Error of 
difference between 
2 proportions 
Z Significance
0-20 c>d 11.49 3.23 P<0.05 Classic 
system 21-40 d>c 11.89 2.14 P<0.05 
0-50 c>d 9.23 4.25 P<0.05 
Grading 
system 51-
150 d>c 11.82 2.43 P<0.05 
  
i Vs di  Score range     
21-40 di>i 8.18 1.51 P>0.05 
Classic 
system 61-
100 i>di 11.31 2.43 P<0.05 
51-
150 di>i 10.03 2.22 P<0.05 Grading 
system 201-
400 i>di 12.24 2.03 P<0.05 
 
Comparing the two scoring systems for non-diabetics (c) and diabetics 9d) 
without infection 
It was observed from the analysis tabulated above (tables 24,25,26) that 
in the lowest score range in both systems (i.e.,0-20 in the 1st and 0-50 in 2nd), 
the proportion of cases of non-diabetics without infection (c) was more than 
 61
that of diabetics without infection (d) category (P<0.05), whereas in the low 
middle score ranges (i.e., 21-40 in the 1st and 51-150 in the 2nd), the proportion 
of cases of diabetes without infection  (d) was higher than that of non-diabetics 
without infection (c) category (P<0.05). Moreover, with reference to table no. 
25, in the grading system, 45.3% of patients in the diabetes without infection 
(d) category had score range of 51-100, while none in this category's (d) cases 
were in the 0-50 range indicating that none of the diabetics in our study had 
inactive neutrophils. Whereas in the classical (1st) scoring system (table 24), 
although 54.5% of patients of (d) category were in the 21-40 range, there was 
also a sizeable representation in the 0-20 range i.e.,24.2%. Hence it was 
inferred that even though both the scoring  systems were able to highlight the 
higher neutrophil activity of diabetics  compared to non-diabetics without 
infection, the same could be better appreciated by the grading system. 
Comparing the two scoring systems for Non-diabetics (i) and diabetics (di) 
with infection 
 It was also observed (from the table 24,25 and 26) that in the higher 
score range in both systems (i.e., 61-100  in the 1st and 200-400 in the 2nd), the 
proportion of cases of diabetics with infection (di) was lower  than that of non-
diabetics with infection (i) category (P<0.05), whereas in the low middle score 
range (i.e., 21-40 in the 1st and 51-150 in the 2nd  system), the proportion of 
cases of diabetics with infection (di) was found to be higher than that of non-
diabetics with infection (i) category, but this difference was statistically 
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significant in the grading system but not in the classic system. Hence it was 
inferred that both the scoring systems showed lower rise in NBT scores in 
diabetics with infection (di) compared to non-diabetics with infection (i) 
probably reflecting a reduced neutrophil activity in diabetics with infection, 
though it was better brought out by the grading system.  
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SUMMARY AND CONCLUSION 
• This study has attempted to analyze the bactericidal function of the 
neutrophils by the simple NBT test in diabetes mellitus. 
• This study has employed both the classical NBT scoring system (based 
on the presence or absence of formazan granules in cytoplasm) and the 
2nd scoring system (based on the grading of staining). 
• The study population included non-diabetics without infection , non-
diabetics with infection, diabetics without infection and diabetics with 
infection. 
Figure 15  
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Figure 16 
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• In this study, higher NBT scores were observed in diabetics when 
compared to non-diabetics without infection.  It could probably be as a 
result of  persistent activation of resting neutrophils in diabetics 
compared to non-diabetics :: [1st scoring system : non-diabetics without 
infection (mean NBT=21.8%); diabetics without infection (mean 
NBT=32.7%). 2nd scoring system: non-diabetics without infection (mean 
NBT=82/400); diabetics without infection (mean NBT=117.2/400)]. 
However there was no significant difference in the ANCs of diabetics 
and non-diabetics without infection. 
• Irrespective of the diabetic status, patients when exposed to infectious 
agents, had  higher mean NBT scores and absolute neutrophil counts, 
thereby confirming  NBT test as a useful test to ascertain the presence of 
infection :: [1st scoring system : non-diabetics with infection (mean 
NBT=76.5%); diabetics with infection (mean NBT=63.4%). 2nd scoring 
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system : non-diabetics with infection (mean NBT=228.5/400); diabetics 
with infection (mean NBT=198.8/400)] 
• However, the mean NBT score of diabetics with infection (63.4%) did 
not reach the higher mean NBT scores of non-diabetics with infection 
(76.5%), probably related to the hyper-excited state of resting 
neutrophils, leading to burn out and reduced ability of neutrophils to 
mount a high respiratory burst activity (defective bactericidal function). 
And this difference has been better highlighted  by the grading system.  
• No correlation was found between NBT scores and gender in our study. 
• There was a positive correlation between NBT scores and absolute 
neutrophil counts in non-diabetics without infection, non-diabetics with 
infection and diabetics without infection. However, a negative 
correlation was observed in diabetics with infection probably also 
indicating a fall in neutrophil function in that population. 
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Pitfalls in our study: 
 Only patients who visited our hospital were chosen for our study. 
Selection was not extended to a wider area.  
 The relationship between duration of diabetes mellitus and NBT scores 
was not analyzed. Only a single blood sugar level evaluated. 
 The degree of control of diabetes mellitus (HbA1c) was not evaluated.  
 This study is only a single point analysis. Serial evaluation of subjects 
has not been done.    
Prospects of Future Studies: 
1. To analyse if NBT test correlates with the severity of diabetes 
mellitus (HbA1c levels). 
2. The feasibility of NBT scoring as a screening test of neutrophil 
function, while evaluating patients with diabetes mellitus, and its 
predictive value in  response to infections. 
3. In view of the low cost of NBT scoring and its technical 
simplicity, the same may be compared to other tests of neutrophil 
function and the scoring standardized.  
4. To in-cooperate grading in NBT scoring to effect a standardized 
evaluation and eliminate inter-observer variation observed in the 
classical scoring. 
5. To re-inforce our observation of increased sensitivity by the 
graded system of scoring by studies with a larger sample size.   
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35 di04 22542/08 46 M N N 0 Y 2 O Peritonitis 8.4 63 34 3 15 150 Ascites  CONS 5.3 74 225 
36 di05 70022/08 70 M N Y 2 Y 3 O UTI 10.2 65 28 7 7 294 Urine  Pseudomanas 6.6 84 199 
37 di08 23728/08 50 M N Y 2 Y 10 I Wound infection 8.2 82 16 2 10 139 Pus  Proteus 6.7 77 300 
38 di11 50426/08 27 M N Y 6 Y 7 I UTI 9 64 34 2 15 64 Urine  E.coli 5.8 26 239 
39 di13 53490/08 60 M Y Y 5 Y 3 O Ulcer foot 9.4 75 20 5 28 270 Pus  Proteus 7.1 54 187 
40 di14 46170/08 58 F N Y 30 Y 10 O Ulcer foot 8.4 60 30 4 35 212 Pus  Pseudomanas 5.0 63  
41 di15 53658/08 45 F N Y 5 Y 10 O Ulcer foot 17.3 88 6 6 30 248 Pus  Klebsiella 15.2 74 311 
42 di16 72745/08 20 M Y Y 2 Y 2 I Enteric fever 8.6 65 33 2 25 216  WIDAL S.typhi 5.6 56 118 
43 di17 55679/08 49 M N Y 6 Y 4 O Ulcer foot 6.6 62 37 1 42 328 Pus  Klebsiella 4.1 88 262 
44 di18 64742/08 45 F N N 0 Y 7 O Ulcer foot 13.1 87 10 3 33 126 Pus  CONS 11.4 84 294 
45 di19 67402/08 44 M N Y 3 Y 4 O Ulcer foot 10.2 52 38 5 10 198 Pus  Klebsiella 5.3 90 223 
46 di20 68202/08 55 M N Y 1 Y 2 O Ulcer foot 29.1 93 5 2 40 500 Pus  CONS 27.1 28 112 
47 di21 67136/08 60 F Y Y 6 Y 15 O Ulcer foot 12.1 80 16 4 22 142 Pus  Pseudomanas 9.7 77 215 
48 di22 70838/08 60 M Y N 0 Y 10 O Ulcer foot 9.5 70 25 5 36 84 Pus  Proteus 6.7 20 116 
49 di24 67494/08 38 M N Y 2 Y 2 O Ulcer foot 17.5 70 28 2 25 134 Pus  Proteus 12.3 32 150 
50 di25 71172/08 42 F N Y 5 Y 7 O Ulcer foot 8.7 59 33 8 14 162 Pus  Klebsiella 5.1 26  
51 di27 68192/08 40 F N N 0 Y 4 O Asymptomatic UTI 7.4 66 33 1 15 173 Urine  E.coli 4.9 54 165 
52 di28 30773/98 57 F N N 0 Y 10 I Asymptomatic UTI 8.7 74 23 3 21 126 Urine  Citrobacter 6.4 87 309 
53 di29 73364/08 60 F Y Y 4 Y 4 O Acute Pyelonephritis 10.4 90 8 2 46 252 Urine  E.coli 9.4 89 289 
54 di30 74429/08 50 M Y Y 4 Y 2 O UTI 6.9 85 12 3 40 105 Urine  E.coli 5.9 54 129 
55 di32 73127/08 66 M N N 0 Y 2 O UTI 9.4 83 14 3 60 162 Urine  Klebsiella 7.8 40 106 
56 di33 73238/08 60 M N Y 10 Y 10 O Ulcer scrotum 8.4 52 40 8 40 199 Pus  Pseudomanas 4.4 87 225 
57 di34 60840/08 55 M Y Y 20 Y 5 O UTI 4 50 45 5 124 108 Urine  Klebsiella 2.0 82 149 
58 di35 75249/08 46 F Y Y 5 Y 12 O UTI 8.8 64 34 2 35 270 Urine  E.coli 5.6 56 184 
59 di36 72432/08 60 F N N 0 Y 8 O Bed sore 10 89 9 2 41 154 Pus  Proteus 8.9 88 251 
60 di37 72723/08 58 F Y Y 5 Y 5 B Ulcer foot 9.6 72 26 2 42 228 Pus  Proteus 6.9 84 173 
61 di38 75463/08 50 F N Y 10 Y 6 B Ulcer foot 7 73 22 5 80 216 Pus  Proteus 5.1 90 193 
62 di39 42346/00 59 M N N 0 Y 2  Asymptomatic UTI 6.5 64 28 4 23 211 Urine  E.coli 4.2 52 117 
63 di41 29292/97 50 M N N 0 Y 2  Asymptomatic UTI 5.8 59 39 2 13 196 Urine  CONS 3.4 57 193 
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64 d01 22187/08 38 M N N Y 2 I DKA 8.7 70 26 4 12 400 Urine   NG 6.1 23 104 
65 d02 24425/08 74 M N N Y 15 I DM Nephropathy 7.4 60 36 4 40 200 Urine   NG  4.4 6 175 
66 d03 22628/08 27 M N N Y 2 B DKA 8.7 62 36 2 35 300 Urine   NG 5.4 28 55 
67 d04 22886/08 40 M N N Y 2 O DM Neuropathy 8.7 65 33 2 25 276 Urine   NG 5.7 37 184 
68 d05 24429/08 40 F N N Y 6 B DM 8.2 68 30 2 7 370 Urine   NG 5.6 23 123 
69 d06 23463/08 75 F N N Y 3 O DM Neuropathy 7.6 62 35 3 25 166 Urine   NG 4.7 28 66 
70 d07 25659/08 78 F N N Y 15 O DM 9.6 55 43 2 25 218 Urine   NG 5.3 56 227 
71 d10 50608/02 59 M N N Y 6 O DM 7.2 54 44 2 8 168 Urine   NG 3.9 27 117 
72 d12 61733/08 31 F N N Y 8 O DM 6.1 72 27 1 24 179 Urine   NG 4.4 23 132 
73 d13 15746 65 M N N Y 15 O DM 8.2 68 28 4 12 188 Urine   NG 5.6 68 189 
74 d14 43515/01 40 F N N Y 5 O DM 5.4 50 46 4 8 202 Urine   NG 2.7 19 71 
75 d15 149376/07 48 F N N Y 7 O DM 8.1 54 42 4 10 180 Urine   NG 4.4 20 54 
76 d16 67801/08 52 M N N Y 4 O DM 6.2 68 30 2 12 144 Urine   NG 4.2 9 95 
77 d17 3560 49 M N N Y 3 O DM 6.6 72 24 4 22 225 Urine   NG 4.8 23 83 
78 d18 1882260 49 F N N Y 7 O DM 8.8 70 28 2 18 228 Urine   NG 6.2 66 156 
79 d20 537907 45 F N N Y 5 B DM 9.2 66 33 1 8 105 Urine   NG 6.1 58 136 
80 d21 10296 48 F N N Y 20 B DM 10.8 72 26 2 10 126 Urine   NG 7.8 91 244 
81 d22 1973 45 F N N Y 4 O DM 7.8 62 34 4 14 202 Urine   NG 4.8 58 138 
82 d24 83407 49 M N N Y 3 O DM 9.5 60 34 6 12 165 Urine   NG 5.7 28 260 
83 d25 404040 55 M N N Y 4 O DM 5.4 52 46 2 26 192 Urine   NG 2.8 25 102 
84 d26 61868/05 55 M N N Y 3 O DM 6.8 66 33 1 8 164 Urine   NG 4.5 17 60 
85 d27 68253/08 58 M N N Y 5 O DM 7.6 58 38 1 6 102 Urine   NG 4.4 32 89 
86 d28 57540/04 60 F N N Y 9 O DM 8.7 70 22 8 10 112 Urine   NG 6.1 22 147 
87 d29 142014 53 F N N Y 14 O DM 9.6 68 30 1 16 160 Urine   NG 6.5 85 140 
88 d30 17716/90 63 M N N Y 18 O DM 5.6 54 35 1 8 186 Urine   NG 3.0 15 110 
89 d31 11101 68 F N N Y 10 O DM 7.2 64 32 2 12 143 Urine   NG 4.6 21 58 
90 d32 53739/05 50 F N N Y 5 O DM 6.4 56 40 4 10 154 Urine   NG 3.6 22 51 
91 d33 38957/99 50 M N N Y 9 O DM 3.6 28 60 12 20 189 Urine   NG 1.0 25 56 
92 d34 54740/03 50 F N N Y 5 O DM 2.7 48 48 4 18 124 Urine   NG 1.3 21 106 
93 d35 1636/01 62 M N N Y 8 O DM 9.2 56 40 4 11 160 Urine   NG 5.2 35 86 
94 d36 94810 59 F N N Y 3 O DM 6.1 64 32 4 13 155 Urine   NG 3.9 33 100 
95 d37 29826/97 60 F N N Y 11 O DM 8 68 24 8 5 110 Urine   NG 5.4 17 81 
96 d38 79018 62 M N N Y 2 O DM with CVA  3.7 48 36 16 14 200 Urine   NG 1.8 19 72 
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97 c01 33 F N N N NA NA Volunteer 8.5 52 46 2 8 84 NA NA NA 4.4 35 50 
98 c02 29 M N N N NA NA Volunteer 5.4 59 40 1 6 80 NA NA NA 3.2 20 56 
99 c03 28 M N N N NA NA Volunteer 9.2 62 38 0 6 105 NA NA NA 5.7 43 22 
100 c04 30 M N N N NA NA Volunteer 7.2 58 29 8 10 94 NA NA NA 4.2 16 36 
101 c05 23 M N N N NA NA Volunteer 7.6 62 36 2 12 84 NA NA NA 4.7 14 72 
102 c07 19 M N N N NA NA Volunteer 6.9 57 43 0 6 102 NA NA NA 3.9 22 84 
103 c08 19 M N N N NA NA Volunteer 5.2 72 25 3 8 90 NA NA NA 3.7 10 72 
104 c09 19 M N N N NA NA Volunteer 8.1 71 22 7 6 88 NA NA NA 5.7 10 132 
105 c10 19 M N N N NA NA Volunteer 6.9 58 33 9 8 102 NA NA NA 4 11 50 
106 c11 19 M N N N NA NA Volunteer 9.6 70 26 4 10 90 NA NA NA 6.7 17 79 
107 c12 19 M N N N NA NA Volunteer 7.6 72 26 2 6 92 NA NA NA 5.5 19 43 
108 c13 19 M N N N NA NA Volunteer 3.8 34 40 12 15 96 NA NA NA 1.2 14 129 
109 c15 20 M N N N NA NA Volunteer 6 52 45 3 20 106 NA NA NA 3.1 20 13 
110 c16 20 M N N N NA NA Volunteer 8 48 40 8 12 84 NA NA NA 3.8 60 38 
111 c17 19 F N N N NA NA Volunteer 9 80 19 1 6 92 NA NA NA 7.2 21 21 
112 c18 20 F N N N NA NA Volunteer 7.5 84 12 1 8 100 NA NA NA 6.3 15 38 
113 c19 19 F N N N NA NA Volunteer 9.6 60 35 3 6 84 NA NA NA 5.7 18 34 
114 c20 19 F N N N NA NA Volunteer 8.4 88 11 1 8 96 NA NA NA 7.4 19 12 
115 c22 25 F N N N NA NA Volunteer 10.6 76 20 2 14 98 NA NA NA 8.1 20 161 
116 c23 18 F N N N NA NA Volunteer 2.8 32 60 8 6 86 NA NA NA 0.9 27 114 
117 c27 18 F N N N NA NA Volunteer 5.2 60 32 8 6 84 NA NA NA 3.1 24 141 
118 c28 32 F N N N NA NA Volunteer 5.8 68 24 4 8 112 NA NA NA 3.9 8  
119 c29 20 F N N N NA NA Volunteer 6.3 68 24 2 12 96 NA NA NA 4.3 22 147 
120 c30 24 M N N N NA NA Volunteer 10.1 60 36 2 10 106 NA NA NA 6.1 35 152 
121 c31 19 F N N N NA NA Volunteer 3.5 56 40 4 6 86 NA NA NA 2 17  
122 c33 41 M N N N NA NA Volunteer 3.1 72 26 2 14 118 NA NA NA 2.2 31 142 
123 c34 20 F N N N NA NA Volunteer 3.5 44 40 12 6 86 NA NA NA 1.5 8 167 
124 c35 34 F N N N NA NA Volunteer 5.1 60 32 4 8 94 NA NA NA 3.1 24 116 
125 c36 28 M N N N NA NA Volunteer 2.8 58 40 2 10 102 NA NA NA 1.6 4 90 
126 C37 30 F N N N NA NA Volunteer 6.2 70 28 2 6 90 NA NA NA 4.3 9 85 
127 c38 20 M N N N NA NA Volunteer 8.6 72 20 8 6 88 NA NA NA 6.2 65  
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Key to Master Chart 
 
B - On Both oral hypoglycemics and insulin 
DKA - Diabetic Keto Acidosis 
DM - Diabetes Mellitus  
E - Eosinophils 
ESR - Erythrocyte Sedimentation Rate 
FBS - Fasting Blood Sugar 
I - On Insulin 
L - Lymphocytes 
N - No / Not on treatment  
NA - Not Applicable  
NG - No Growth  
O - On Oral hypoglycemic drug 
P - Polymorphs 
TLC - Total Leucocyte Count 
Y - Yes 
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ANNEXURES 
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                                                      PROFORMA 
 
Slide No:   _____ 
Name:                                       Age:                                       Sex: 
IP NO:                                                         Unit/Ward 
Occupation:                                                                     Address: 
History: 
Fever:      Yes _____        No______                          Duration: 
 
 
Diabetes:  Duration                                                    Type: I  ___      II.   _____ 
 Oral Hypoglycemics 
 Insulin 
Antibiotic:                                                                    Duration: 
Other Treatments: 
 
 
General Examination: 
Skin / subcutaneous 
 
Nails: 
Foot: 
Eye: 
NT: 
Oral cavity: 
CVS: 
RS: 
CNS: 
P/A: 
Perineum/Ext. Gen 
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Investigations: 
TLC:                                                                            FBS: 
DLC:                                                                           
ESR:                         mm/hr                                    Urine Routine: 
       Culture 
 
 
      
 
Other Investigations: 
 
Summary: 
 
Diabetes:      Yes___    No____ 
 
Infection:  Yes ____     No ______                         Diagnosis /  Type of Infection: 
___________________ 
NBT Score: 
A. Classical scoring system: 
B. Grading system: 
 
 
 
 
 
 
 
   
